Latest Ursodiol Stories
FDA approves oral therapy as a first-in-class treatment BALTIMORE, March 17, 2015 /PRNewswire-USNewswire/ -- Asklepion Pharmaceuticals, LLC. today announced that the U.S.
GOTHENBURG, Sweden, February 5, 2015 /PRNewswire/ -- Albireo today announced initiation of a phase II trial with A4250, the company's lead compound for cholestatic liver
TEL AVIV, Israel, July 22, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements.
SAN DIEGO, April 8, 2014 /PRNewswire/ -- MEI Pharma, Inc.
DUBLIN, February 28, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/4lmkfc/ursodeoxycholic) has announced the addition of the "Ursodeoxycholic
- Emitting flashes of light; glittering.